The founders of cardiovascular gene therapy: Jeffrey Isner — a pioneer of therapeutic angiogenesis

The article presents a historical reference about the founders of cardiovascular gene therapy, the first gene therapy clinical application carried out by doctor Jaffrey Isner in patient with critical limb ischemia and his invaluable contribution to thе area of cardiovascular gene therapy.

1. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine. 1971;285:1182–1186.

2. Svet-Moldavsky GJ, Chimishkyan KL. Tumor angiogenesis factor for revascularization in ischemia and myocardial infarction. Lancet. 1977 Apr 23;1(8017):913.

3. Isner JM, Donaldson RF, Deckelbaum LI, Clarke RH, Laliberte SM, Ucci AA, et al. The excimer laser: gross, light microscopic, and ultrastructural analysis of potential advantages for use in laser therapy of cardiovascular disease. J Am Coll Cardiol. 1985;6:1102–1109.

4. Clarke RH, Isner JM, Donaldson RF, Jones G. Gas chromatographic-light microscopic correlative analysis of excimer laser photoablation of cardiovascular tissues. Evidence for a thermal mechanism. Circ Res. 1987;60:429–439.

5. Steg PG, Gal D, Rongione AJ, DeJesus ST, Clarke RH, Isner JM. Effect of argon laser irradiation on rabbit aortic smooth muscle: evidence for endothelium independent contraction and relaxation. Cardiovasc Res. 1988;22:747–753.

6. Gal D, Chokshi SK, Mosseri M, Clarke RH, Isner JM. Percutaneou delivery of low-level laser energy reverses histamine-induced spasm in atherosclerotic yucatan microswine. Circulation. 1992;86:756–768.

7. Pickering JG, Weir L, Rosenfield K, Stetz J, Isner JM. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J Am Coll Cardiol. 1992;20:1430–1439.

8. Pickering JG, Bacha PA, Weir L, Jekanowski J, Nichols JC, Isner JM. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. J Clin Invest. 1993;91:724–729.

9. Isner JM, Kearney, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703–2711.

10. Losordo DW, Rosenfield K, Pieczek A, Baker K, Harding M, Isner JM. How does angioplasty work? Serial in vivo morphometric analysis of mechanisms of angioplasty in humans using intravascular ultrasound. Circulation. 1992;86:1845–1858.

11. van der Zee R, Zollman F, Passeri J, Lekutat C, Silver M, Isner JM. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997;95:1030–1037.

12. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nature Med. 1997;3:879–886.

13. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Sullivan A, Isner JM Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via receptor tyrosine kinase Flk-1 mediated production of nitric oxide and prostacyclin. Circulation. 1998;97:99–107.

14. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567–2578.

15. Namiki A, Brogi E, Kearney M, Wu T, Couffinhal T, Varticovski L, Isner JM. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chemistry. 1995;270:31189 –31195.

16. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest. 1996;97:469–476.

17. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Schatteman G, Isner JM. Isolation of putative endothelial progenitor cells for angiogenesis. Science. 1997;275:964–967.

18. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. The Tie2 receptor ligands, angioprotein-1 and angiopoietin-2 modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233–240.

19. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998 Nov 10;98(19):2081–2087.

20. van der Zee R, Zollman F, Passeri J, Lekutat C, Silver M, Isner JM. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997;95:1030–1037.

21. Leclerc G, Gal D, Nikol S, Kearney M, Weir L, Isner JM. Percutaneous arterial gene transfer in a rabbit model efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest. 1992;90:936–944.

22. Losordo DW, Leclerc G, Gal D, Weir L, Takeshita S, Isner JM. Use of the rabbit ear artery to serially assess foreign protein secretion after site-specified arterial gene transfer in vivo: evidence that anatomic identification of successful. Circulation. 1994;89:785–792.

23. Gal D, Weir L, Leclerc G, Pickering JG, Hogan J, Isner JM. Direct myocardial transfection in two animal models: evaluation of parameters affecting gene expression and percutaneous gene delivery. Lab Invest. 1993;68:18–25.

24. Takeshita S, Gal D, Leclerc G, Pickering JG, Riessen R, Weir L, Isner JM. Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation following vascular injury. J Clin Invest. 1994;93:652–661.

25. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM. Arterial gene transfer using pure DNA applied directly to hydrogel-coated angioplasty balloon. Hum Gene Ther. 1993;4:749–758.

26. Takeshita S, Tsurumi Y, Couffinhal T, Asahara T, Bauters C, Symes JF, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 1996;75:487–502.

27. Takeshita S, Zheng LP, Brogi E, Kearney M, Asahara T, Pu LQ, et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest. 1994;93:662–670.

28. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Physiologic assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 267 Heart Circ Physiol. 1994;36:H1263–H1271.

29. Brogi E, Wu T, Namiki S, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, while hypoxia upregulates VEGF expression only. Circulation. 1994;90:649–652.

30. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Recovery of disturbed endothelium-dependent flow in the collateral- perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation. 1995;91:2802– 2809.

31. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, et al. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest. 1995;95:2662–2671.

32. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, et al. Time course of increased cellular proliferation in collateral arteries following administration of vascular endothelial growth factor in a rabbit mode of lower limb vascular insufficiency. Am J Pathol. 1995;147:1649–1660.

33. Asahara T, Bauters C, Pastore CJ, Kearney M, Rossow S, Bunting S, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in ballooninjured rat carotid artery. Circulation. 1995;91:2793–2801. 34. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. Trends Cardiovasc Med. 2008 Jan;18(1):33–37.

34. Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013 Apr 26;112(9):1288–1302.

35. Renault MA, Losordo DW. Therapeutic myocardial angiogenesis. Microvasc Res. 2007; 74(2-3):159-71.

36. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res. 2002 Apr;11(2):171–178.

37. Salybekov AA, Kobayashi S, Asahara T. Characterization of Endothelial Progenitor Cell: Past, Present, and Future. Int J Mol Sci. 2022 Jul 12;23(14):7697.

38. Isner JM. Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis Am J Cardiol. 1998 Nov 19;82(10A):63S–64S.

39. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 Mar 31;97(12):1114–1123.

40. Isner JM. Myocardial gene therapy. Nature. 2002 Jan 10;415(6868):234–239.

41. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009 Oct 9;105(8):724–736.

42. Roncalli J, Tongers J, Losordo DW. Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure. Arch Cardiovasc Dis. 2010 AugSep;103(8–9):469–476.

43. Magadum A, Kaur K, Zangi L. mRNA-Based Protein Replacement Therapy for the Heart. Mol Ther. 2019 Apr 10;27(4):785–793.

44. Shimamura M, Nakagami H, Taniyama Y, Morishita R. Gene therapy for peripheral arterial disease. Expert Opin Biol Ther. 2014 Aug;14(8):1175–1184.

45. Швальб П.Г., Гавриленко А.В., Калинин Р.Е. и др. Эффективность и безопасность применения препарата «Неоваскулген» в комплексной терапии пациентов с хронической ишемией нижних конечностей (2б–3 фаза клинических испытаний). КТТИ. 2011;3:76–83.

46. Barć P, Antkiewicz M, Śliwa B, Frączkowska K, Guziński M, Dawiskiba T, et al. Double VEGF/ HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus. J Cardiovasc Transl Res. 2021 Jun;14(3):409–415.

47. Талицкий К.Т., Булкина О.С., Арефьева Т.И., Парфенова Е.В., Карпов Ю.А. Эффективность терапевтического ангиогенеза у больных с хронической ишемией нижних конечностей. КТТИ. 2011;3(VI):89–98.

48. Бокерия Л.А., Голухова Е.З., Еремеева М.В. и др. Первый опыт клинического применения терапевтического ангиогенеза с использованием гена VEGF165 человека. Бюллетень НЦССХ им Бакулева РАМН «Сердечно-сосудистые заболевания. Креативная кардиология. Новые технологии в диагностике и лечении заболеваний сердца», 2004;4:134–142.

49. Бокерия Л.А., Еремеева М.В., Самсонова Н.Н. Динамика показателей гемореологии у пациентов с хронической ишемией нижних конечностей в результате стимуляции ангиогенеза. Креативная кардиология. 2013;1:66–73.

50. Бокерия Л.А., Георгиев Г.П., Голухова Е.З. и др. Возможности использования генных и клеточных технологий для лечения сердечно-сосудистых заболеваний. Бюллетень НЦССХ им Бакулева РАМН «Сердечно-сосудистые заболевания. Креативная кардиология. Новые технологии в диагностике и лечении заболеваний сердца». 2004;3:19–38.

51. Makarevich P., Tsokolaeva Z., Shevelev A. et al. Combined Transfer of Human VEGF165 and HGF Genes Renders Potent Angiogenic Effect in Ischemic Skeletal Muscle. PLoS ONE. 2012;7(6):e38776.

52. Makarevich PI, Dergilev KV, Tsokolaeva ZI, Boldyreva MA, Shevchenko EK, Gluhanyuk EV, et al. Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS One. 2018 May 22;13(5):e0197566.

53. Stafeev I IS, Boldyreva MA, Michurina SS, Agareva MY, Radnaeva AV, Menshikov MY, et al. The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle. Cells. 2022 Nov 29;11(23):3824.

54. Traktuev DO, Tsokolaeva ZI, Shevelev AA, Talitskiy KA, Stepanova VV, Johnstone BH, et al. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther. 2007 Nov;15(11):1939–1946.

55. Плотников МВ. Ризванов АА, Масгутов РФ, Мавликеев МО, Салафутдинов ИИ, Газизов ИМ и др. Первый клинический опыт применения прямой генной терапии VEGF и bFGF при лечении пациентов с критической ишемией нижних конечностей. Клеточная трансплантология и тканевая инженерия. 2012. Т. VII, № 3: 180-184.

56. Гавриленко А.В., Воронов Д.А., Бочков Н.П. Комплексное хирургическое лечение пациентов с хронической ишемией нижних конечностей с использованием генных индукторов ангиогенеза. Хирургия. Журнал им. Н.И. Пирогова. 2013;2:25–29.

57. James J. Ferguson. Editorial. In Memoriam: Jeffrey Michael Isner 1947–2001. Texas Heart Institute Journal. 2001;28(4):247–248. 59. Roberts WC. Jeffrey Michael Isner, MD: a conversation with the editor. Am J Cardiol. 1999; 82:68–88.